The 2019 World Congress on Controversies in Multiple Myeloma (COMy) was held in Paris, France on May 16–18. Experts in the field came together to discuss and debate the latest controversies in the field.

COMy 2019

16–18 May 2019 | Paris, France

COMy 2019

16–18 May 2019 | Paris, France

The 2019 World Congress on Controversies in Multiple Myeloma (COMy) was held in Paris, France on May 16–18. Experts in the field came together to discuss and debate the latest controversies in the field.

CAR-T cells for myeloma: experience from China 2:37
CAR-T cells for myeloma: experience from China
He Huang • 16 May 2019
AL amyloidosis: an update from Dr Merlini 1:23
AL amyloidosis: an update from Dr Merlini
Giampaolo Merlini • 16 May 2019
Daratumumab practical considerations in MM 3:36
Daratumumab practical considerations in MM
Torben Plesner • 16 May 2019
The case for IMiDs in relapsed MM 2:49
The case for IMiDs in relapsed MM
Meral Beksac • 16 May 2019
Risk stratification of MGUS 1:47
Risk stratification of MGUS
Vincent Rajkumar • 16 May 2019
Immune-mediated mechanisms of progression in MGUS and smouldering myeloma 0:54
Immune-mediated mechanisms of progression in MGUS and smouldering myeloma
Irene Ghobrial • 16 May 2019
The use of imaging to determine MRD 3:12
The use of imaging to determine MRD
Elena Zamagni • 17 May 2019
Update on WM biology and therapy 2:15
Update on WM biology and therapy
Steven Treon • 16 May 2019
Genomic advances in MM disease biology 0:39
Genomic advances in MM disease biology
Irene Ghobrial • 16 May 2019
Treating younger MM patients: finding the optimal induction regimen 2:18
Treating younger MM patients: finding the optimal induction regimen
Joan Bladé • 17 May 2019
CyborD-DARA combination in first-line treatment for multiple myeloma 3:58
CyborD-DARA combination in first-line treatment for multiple myeloma
Michael O’Dwyer
Progression of multiple myeloma novel therapies with Prof. Nagler 2:43
Progression of multiple myeloma novel therapies with Prof. Nagler
Arnon Nagler • 17 May 2019
Genomic patterns in smoldering myeloma enhance timing of treatment initiation 3:37
Genomic patterns in smoldering myeloma enhance timing of treatment initiation
Nikhil Munshi • 17 May 2019
Three key messages for MRD negativity in multiple myeloma 3:38
Three key messages for MRD negativity in multiple myeloma
Nikhil Munshi • 17 May 2019
Rationale for NK-cell therapy in myeloma 3:21
Rationale for NK-cell therapy in myeloma
Michael O’Dwyer • 17 May 2019
Delaying transplant in the young and fit MM patient 2:16
Delaying transplant in the young and fit MM patient
Graham Jackson • 17 May 2019
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals